Go Pro
→ WATCH THIS BEFORE DECEMBER 8th!! (From Paradigm Press) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aadi Bioscience, Inc. stock logo
AADI
Aadi Bioscience
$3.74
-3.1%		$4.30
$1.21
▼
$3.81
$92.37M0.68261,100 shs166,982 shs
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
$1.20
-3.2%		$1.04
$0.76
▼
$3.31
$96.47M1.46868,063 shs368,883 shs
DT Cloud Star Acquisition Corporation stock logo
DTSQ
DT Cloud Star Acquisition
$11.61
+1.0%		$11.39
$10.45
▼
$12.90
$102.36M-0.01351 shs868 shs
Evaxion A/S - Sponsored ADR stock logo
EVAX
Evaxion A/S
$3.24
-3.0%		$3.10
$2.77
▼
$12.15
$30.13M0.2646,817 shs55,694 shs
The 7 Hottest IPO Stories of 2026 Cover
The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aadi Bioscience, Inc. stock logo
AADI
Aadi Bioscience
0.00%-10.95%-23.20%-10.10%+92.78%
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
0.00%-9.49%+31.91%-2.36%-39.81%
DT Cloud Star Acquisition Corporation stock logo
DTSQ
DT Cloud Star Acquisition
0.00%-1.12%+0.79%+1.91%+8.94%
Evaxion A/S - Sponsored ADR stock logo
EVAX
Evaxion A/S
0.00%+2.14%+10.96%+4.37%-17.33%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aadi Bioscience, Inc. stock logo
AADI
Aadi Bioscience
$3.74
-3.1%		$4.30
$1.21
▼
$3.81
$92.37M0.68261,100 shs166,982 shs
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
$1.20
-3.2%		$1.04
$0.76
▼
$3.31
$96.47M1.46868,063 shs368,883 shs
DT Cloud Star Acquisition Corporation stock logo
DTSQ
DT Cloud Star Acquisition
$11.61
+1.0%		$11.39
$10.45
▼
$12.90
$102.36M-0.01351 shs868 shs
Evaxion A/S - Sponsored ADR stock logo
EVAX
Evaxion A/S
$3.24
-3.0%		$3.10
$2.77
▼
$12.15
$30.13M0.2646,817 shs55,694 shs
The 7 Hottest IPO Stories of 2026 Cover
The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aadi Bioscience, Inc. stock logo
AADI
Aadi Bioscience
0.00%-10.95%-23.20%-10.10%+92.78%
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
0.00%-9.49%+31.91%-2.36%-39.81%
DT Cloud Star Acquisition Corporation stock logo
DTSQ
DT Cloud Star Acquisition
0.00%-1.12%+0.79%+1.91%+8.94%
Evaxion A/S - Sponsored ADR stock logo
EVAX
Evaxion A/S
0.00%+2.14%+10.96%+4.37%-17.33%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aadi Bioscience, Inc. stock logo
AADI
Aadi Bioscience
0.00
N/AN/AN/A
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
2.29
Hold$7.50525.00% Upside
DT Cloud Star Acquisition Corporation stock logo
DTSQ
DT Cloud Star Acquisition
2.00
HoldN/AN/A
Evaxion A/S - Sponsored ADR stock logo
EVAX
Evaxion A/S
2.67
Moderate Buy$11.00239.51% Upside

Current Analyst Ratings Breakdown

Latest EVAX, CRDF, DTSQ, and AADI Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/22/2026
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
9/15/2026
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeNeutral ➝ Buy
9/4/2026
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
8/19/2026
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
8/11/2026
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
William Blair logo
William Blair
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeOutperform ➝ Market Perform
8/5/2026
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
7/21/2026
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
7/13/2026
DT Cloud Star Acquisition Corporation stock logo
DTSQ
DT Cloud Star Acquisition
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (D+) ➝ Hold (C-)
7/9/2026
Evaxion A/S - Sponsored ADR stock logo
EVAX
Evaxion A/S
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
6/29/2026
DT Cloud Star Acquisition Corporation stock logo
DTSQ
DT Cloud Star Acquisition
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D+)
(Data available from 9/28/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aadi Bioscience, Inc. stock logo
AADI
Aadi Bioscience
$25.07M3.68N/AN/A$4.29 per share0.87
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
$590K158.22N/AN/A$0.67 per share1.79
DT Cloud Star Acquisition Corporation stock logo
DTSQ
DT Cloud Star Acquisition
N/AN/AN/AN/AN/AN/A
Evaxion A/S - Sponsored ADR stock logo
EVAX
Evaxion A/S
$7.53M3.88N/AN/A$2.04 per share1.59
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aadi Bioscience, Inc. stock logo
AADI
Aadi Bioscience
-$65.76M-$2.35N/AN/AN/A-246.06%-71.87%-57.28%N/A
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
-$45.85M-$0.60N/AN/AN/A-7,885.43%-103.10%-75.52%11/5/2026 (Estimated)
DT Cloud Star Acquisition Corporation stock logo
DTSQ
DT Cloud Star Acquisition
N/AN/AN/AN/AN/AN/AN/AN/AN/A
Evaxion A/S - Sponsored ADR stock logo
EVAX
Evaxion A/S
-$7.71M-$1.21N/AN/AN/AN/A-61.43%-34.23%11/5/2026 (Estimated)

Latest EVAX, CRDF, DTSQ, and AADI Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/11/2026Q2 2026
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
-$0.1196-$0.14-$0.0204-$0.14$0.06 million$0.10 million
8/3/2026Q2 2026
DT Cloud Star Acquisition Corporation stock logo
DTSQ
DT Cloud Star Acquisition
N/A$0.0630N/A$0.0630N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Aadi Bioscience, Inc. stock logo
AADI
Aadi Bioscience
N/AN/AN/AN/AN/A
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
N/AN/AN/AN/AN/A
DT Cloud Star Acquisition Corporation stock logo
DTSQ
DT Cloud Star Acquisition
N/AN/AN/AN/AN/A
Evaxion A/S - Sponsored ADR stock logo
EVAX
Evaxion A/S
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aadi Bioscience, Inc. stock logo
AADI
Aadi Bioscience
N/A
4.89
4.54
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
N/A
3.30
3.30
DT Cloud Star Acquisition Corporation stock logo
DTSQ
DT Cloud Star Acquisition
N/AN/AN/A
Evaxion A/S - Sponsored ADR stock logo
EVAX
Evaxion A/S
0.69
5.06
5.06

Institutional Ownership

CompanyInstitutional Ownership
Aadi Bioscience, Inc. stock logo
AADI
Aadi Bioscience
52.08%
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
16.29%
DT Cloud Star Acquisition Corporation stock logo
DTSQ
DT Cloud Star Acquisition
N/A
Evaxion A/S - Sponsored ADR stock logo
EVAX
Evaxion A/S
11.04%

Insider Ownership

CompanyInsider Ownership
Aadi Bioscience, Inc. stock logo
AADI
Aadi Bioscience
37.30%
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
8.80%
DT Cloud Star Acquisition Corporation stock logo
DTSQ
DT Cloud Star Acquisition
52.90%
Evaxion A/S - Sponsored ADR stock logo
EVAX
Evaxion A/S
41.64%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aadi Bioscience, Inc. stock logo
AADI
Aadi Bioscience
4024.70 million15.49 millionNo Data
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
3177.79 million70.95 millionOptionable
DT Cloud Star Acquisition Corporation stock logo
DTSQ
DT Cloud Star Acquisition
38.90 million4.19 millionN/A
Evaxion A/S - Sponsored ADR stock logo
EVAX
Evaxion A/S
469.02 million5.27 millionNo Data

Recent News About These Companies

Evaxion A/S - Sponsored ADR (NASDAQ:EVAX) Given Consensus Rating of "Moderate Buy" by Brokerages
September 22, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31039427
Head-To-Head Survey: argenex (NASDAQ:ARGX) and Evaxion A/S (NASDAQ:EVAX)
September 20, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31034978
Evaxion A/S (NASDAQ:EVAX) and AnaptysBio (NASDAQ:ANAB) Financial Analysis
September 20, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31033868
Critical Review: Taysha Gene Therapies (NASDAQ:TSHA) vs. Evaxion A/S (NASDAQ:EVAX)
September 18, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31031444
Evaxion applies its AI-Immunology™ platform in autoimmune diseases
September 14, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/14/3361050/0/en/evaxion-applies-its-ai-immunology-platform-in-autoimmune-diseases.html
Merck (MRK) Takes An AI Vaccine Stake And Expands Its Discovery Playbook
August 23, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/merck-mrk-takes-ai-vaccine-190704509.html
Analysts Offer Insights on Healthcare Companies: Evaxion Biotech (EVAX) and Boston Scientific (BSX)
August 22, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/BSX/pressreleases/3985823/analysts-offer-insights-on-healthcare-companies-evaxion-biotech-evax-and-boston-scientific-bsx/
Can Merck & Company (MRK)’s Stake in Evaxion A/S (EVAX) Validate the Potential of AI-Driven Vaccine Discovery?
August 20, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/merck-company-mrk-stake-evaxion-220634079.html
Evaxion presents business update
August 20, 2026  |  thepharmaletter.comT
Evaxion A/S (EVAX) Q2 2026 Earnings Call Transcript
August 20, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4938779-evaxion-a-s-evax-q2-2026-earnings-call-transcript
Evaxion announces business update and second quarter 2026 financial results
August 20, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/20/3348249/0/en/evaxion-announces-business-update-and-second-quarter-2026-financial-results.html
Evaxion scraps solid tumor vaccine to focus on Duke-partnered brain cancer candidate
August 17, 2026  |  fiercebiotech.comF
Evaxion expands and refocuses R&D pipeline with EVX-05, an AI-designed off-the-shelf brain cancer vaccine program
August 17, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/17/3346015/0/en/evaxion-expands-and-refocuses-r-d-pipeline-with-evx-05-an-ai-designed-off-the-shelf-brain-cancer-vaccine-program.html
Evaxion to announce business update and second quarter 2026 financial results on August 20, 2026
August 14, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/14/3345275/0/en/evaxion-to-announce-business-update-and-second-quarter-2026-financial-results-on-august-20-2026.html
Evaxion to present three-year clinical efficacy data for personalized cancer vaccine EVX-01 at the ESMO Congress 2026
July 17, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/17/3329028/0/en/evaxion-to-present-three-year-clinical-efficacy-data-for-personalized-cancer-vaccine-evx-01-at-the-esmo-congress-2026.html
Evaxion presents new preclinical data for cytomegalovirus vaccine program EVX-V1
July 12, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/12/3325846/0/en/evaxion-presents-new-preclinical-data-for-cytomegalovirus-vaccine-program-evx-v1.html
Evaxion to present new preclinical data for cytomegalovirus vaccine candidate EVX-V1 at the International Herpesvirus Workshop
July 1, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/01/3320532/0/en/evaxion-to-present-new-preclinical-data-for-cytomegalovirus-vaccine-candidate-evx-v1-at-the-international-herpesvirus-workshop.html
Evaxion receives Prix Galien UK Award for Best digital health solution
June 12, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/12/3310899/0/en/evaxion-receives-prix-galien-uk-award-for-best-digital-health-solution.html
Evaxion presents new preclinical data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia
June 11, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/11/3310196/0/en/evaxion-presents-new-preclinical-data-for-evx-04-an-off-the-shelf-therapeutic-vaccine-for-acute-myeloid-leukemia.html
Evaxion A/S Sponsored ADR
May 21, 2026  |  edition.cnn.comhttps://edition.cnn.com/markets/stocks/EVAX

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aadi Bioscience stock logo

Aadi Bioscience NASDAQ:AADI

$3.74 -0.12 (-3.11%)
As of 09/25/2026

Aadi Bioscience, Inc., a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa. The company is also involved in evaluating FYARRO in cancers, including indications targeting specific genomic alterations that activate the mTOR pathway. Aadi Bioscience, Inc. was incorporated in 2007 and is headquartered in Pacific Palisades, California.

Cardiff Oncology stock logo

Cardiff Oncology NASDAQ:CRDF

$1.20 -0.04 (-3.23%)
Closing price 04:00 PM Eastern
Extended Trading
$1.20 +0.01 (+0.42%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

DT Cloud Star Acquisition stock logo

DT Cloud Star Acquisition NASDAQ:DTSQ

$11.61 +0.11 (+0.96%)
Closing price 03:54 PM Eastern
Extended Trading
$11.54 -0.07 (-0.65%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

DT Cloud Star Acquisition Corporation focuses on effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or similar business combination with one or more businesses or entities. The company was incorporated in 2022 and is based in Brooklyn, New York.

Evaxion A/S stock logo

Evaxion A/S NASDAQ:EVAX

$3.24 -0.10 (-2.99%)
Closing price 04:00 PM Eastern
Extended Trading
$3.27 +0.03 (+0.99%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers. Its programs also include some vaccines that are in pre-clinical stage, which includes EVX-B1 for the prevention of S. aureus-induced skin and soft tissue infections in patients undergoing elective abdominal hernia surgery; EVX-B2 to target diseases caused by N. gonorrhoeae; EVX-B3 for eliciting strong humoral antibody and cellular immune response to the bacterial pathogen; and EVX-V1, viral vaccine product candidate for targeting Cytomegalovirus. Evaxion Biotech A/S was incorporated in 2008 and is based in Horsholm, Denmark.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas